Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 28, 2017 - Issue 5
Submit an article Journal homepage
710
Views
19
CrossRef citations to date
0
Altmetric
Surgery & Cancer

The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study

Rungsima WanitphakdeedechaDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-3926-2193View further author information
ORCID Icon,
Chanida UngaksornpairoteDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; View further author information
,
Arisa KaewkesDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; View further author information
,
Angkana SathaworawongDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; View further author information
,
Nittaya LektrakulDepartment of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandView further author information
&
Woraphong ManuskiattiDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; View further author information
Pages 443-446 | Received 03 Sep 2016, Accepted 17 Nov 2016, Published online: 06 Dec 2016

References

  • Dasgupta BR. Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York: Springer, 1993.
  • Lew F. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002;18:S142–S6.
  • Botox (Allergan Inc, Irvine). Summary of product characteristic (SPC). [WWW document]. 2014. Available from: https://www.medicines.org.uk/emc/medicine/20564. Accessed May 23, 2015.
  • Small R. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90:168–75.
  • Kim CS, Song KY, Min KM, An YD. Method for Production of Botulinum Toxin, 2014. (Korea; PCT-KR2014-004003).
  • Kim CS, Jang WS, Son IP, et al. Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle. Hum Exp Toxicol. 2013;32:914–20.
  • Won CH, Kim HK, Kim BJ, et al. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol. 2015;54:227–34.
  • Nam HS, Park YG, Paik NJ, et al. Efficacy and safety of Nabota in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial. J Neurol Sci. 2015;357:192–7.
  • Bas B, Ozan B, Muglali M, Celebi N. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases. Med Oral Patol Oral Cir Bucal. 2010;15:e649–52.
  • No YA, Ahn BH, Kim BJ, et al. Three-dimensional CT might be a potential evaluation modality in correction of a symmetrical masseter muscle hypertrophy by botulinum toxin injection. J Cosmet Laser Ther. 2016;18:113–5.
  • Baek SM, Baek RM, Shin MS. Refinement in aesthetic contouring of the prominent mandibular angle. Aesthetic Plast Surg. 1994;18:283–9.
  • Kim TG, Lee JH, Cho YK. Inverted V-shape osteotomy with central strip resection: a simultaneous narrowing and vertical reduction genioplasty. Plast Reconst Surg Glob Open. 2014;2:e227. doi: 10.1097/GOX.0000000000000169.
  • Yoon ES, Seo YS, Kang DH, et al. Analysis of incidences and types of complications in mandibular angle ostectomy in Koreans. Ann Plast Surg. 2006;57:541–4.
  • Andrade NN, Deshpande GS. Use of botulinum toxin (Botox) in the management of masseter muscle hypertrophy: a simplified technique. Plast Reconstr Surg. 2011;128:24e–6e.
  • Yu CC, Chen PK, Chen YR. Botulinum toxin A for lower facial contouring: a prospective study. Aesthetic Plast Surg. 2007;31:445–51.
  • Lee SH, Wee SH, Kim HJ, et al. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy; A split-face study in 25 Korean patients. J Dermatolog Treat. 2013;24:133–6.
  • Lee JH, Park JH, Lee SK, et al. Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. J Dermatolog Treat. 2014;25:326–30.
  • Aydil B, Basaran B, Unsaler S, Suoglu Y. The use of botulinum toxin type A in masseter hypertrophy: long-term effects and lasting improvement. Kulak Burun Bogaz Ihtis Derg. 2012;22:249–53.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.